{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:02Z","timestamp":1707524462932},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,4]]},"DOI":"10.7759\/cureus.20916","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T08:09:22Z","timestamp":1641283762000},"source":"Crossref","is-referenced-by-count":0,"title":["Idiopathic Pulmonary Fibrosis Complicated by Adenocarcinoma and Organizing Pneumonia"],"prefix":"10.7759","author":[{"given":"Yu","family":"Inutsuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoshi","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikiko","family":"Hashisako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiko","family":"Ogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuma","family":"Asoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashige","family":"Maeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu G","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, et al.. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011, 183:788-824. 10.1164\/rccm.2009-040GL","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer DJ","year":"2018","unstructured":"Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018, 378:1811-23. 10.1056\/NEJMra1705751","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu G","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al.. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018, 198:e44-68. 10.1164\/rccm.201807-1255ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210177","article-title":"Timing of onset of symptoms in people with idiopathic pulmonary fibrosis","author":"Hewson T","year":"2017","unstructured":"Hewson T, McKeever TM, Gibson JE, Navaratnam V, Hubbard RB, Hutchinson JP. Timing of onset of symptoms in people with idiopathic pulmonary fibrosis. Thorax. 2017, 10.1136\/thoraxjnl-2017-210177","journal-title":"Thorax"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.1995.tb03417.x","article-title":"Lung cancer associated with usual interstitial pneumonia","volume":"45","author":"Matsushita H","year":"1995","unstructured":"Matsushita H, Tanaka S, Saiki Y, Hara M, Nakata K, Tanimura S, Banba J. Lung cancer associated with usual interstitial pneumonia. Pathol Int. 1995, 45:925-32. 10.1111\/j.1440-1827.1995.tb03417.x","journal-title":"Pathol Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.1.9906062","article-title":"Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study","volume":"161","author":"Hubbard R","year":"2000","unstructured":"Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000, 161:5-8. 10.1164\/ajrccm.161.1.9906062","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-0905-8","article-title":"Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"19","author":"Yoo H","year":"2019","unstructured":"Yoo H, Jeong BH, Chung MJ, Lee KS, Kwon OJ, Chung MP. Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2019, 19:149. 10.1186\/s12890-019-0905-8","journal-title":"BMC Pulm Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0169-5002(01)00405-6","article-title":"Organizing pneumonia adjacent to lung cancer: frequency and clinico-pathologic features","volume":"35","author":"Romero S","year":"2002","unstructured":"Romero S, Barroso E, Rodriguez-Paniagua M, Aranda FI. Organizing pneumonia adjacent to lung cancer: frequency and clinico-pathologic features. Lung Cancer. 2002, 35:195-201. 10.1016\/s0169-5002(01)00405-6","journal-title":"Lung Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1510\/icvts.2011.275065","article-title":"Coexistence of a pulmonary adenocarcinoma with a focal organizing pneumonia","volume":"13","author":"Eguchi T","year":"2011","unstructured":"Eguchi T, Takasuna K, Fujiwara M, Yoshida K. Coexistence of a pulmonary adenocarcinoma with a focal organizing pneumonia. Interact Cardiovasc Thorac Surg. 2011, 13:444-6. 10.1510\/icvts.2011.275065","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000075658","article-title":"An unusual case of bronchiolitis obliterans organizing pneumonia concomitant with bronchioloalveolar carcinoma","volume":"71","author":"Song J","year":"2004","unstructured":"Song J, Gorgan L, Corkey R, Kwa SL. An unusual case of bronchiolitis obliterans organizing pneumonia concomitant with bronchioloalveolar carcinoma. Respiration. 2004, 71:95-7. 10.1159\/000075658","journal-title":"Respiration"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.12.016","article-title":"The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation","volume":"83","author":"Duruisseaux M","year":"2014","unstructured":"Duruisseaux M, Antoine M, Rabbe N, et al.. The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentation. Lung Cancer. 2014, 83:334-40. 10.1016\/j.lungcan.2013.12.016","journal-title":"Lung Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00301","article-title":"Deleterious pulmonary surfactant system gene mutations in lung adenocarcinomas associated with usual interstitial pneumonia","author":"Honda T","year":"2018","unstructured":"Honda T, Sakashita H, Masai K, et al.. Deleterious pulmonary surfactant system gene mutations in lung adenocarcinomas associated with usual interstitial pneumonia. JCO Precis Oncol. 2018, 10.1200\/PO.17.00301","journal-title":"JCO Precis Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddw014","article-title":"Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer","volume":"25","author":"Nathan N","year":"2016","unstructured":"Nathan N, Giraud V, Picard C, et al.. Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. Hum Mol Genet. 2016, 25:1457-67. 10.1093\/hmg\/ddw014","journal-title":"Hum Mol Genet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0029-2019","article-title":"What have we learned from basic science studies on idiopathic pulmonary fibrosis?","volume":"28","author":"Yanagihara T","year":"2019","unstructured":"Yanagihara T, Sato S, Upagupta C, Kolb M. What have we learned from basic science studies on idiopathic pulmonary fibrosis?. Eur Respir Rev. 2019, 28:190029. 10.1183\/16000617.0029-2019","journal-title":"Eur Respir Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14488","article-title":"Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis","volume":"111","author":"Otsubo K","year":"2020","unstructured":"Otsubo K, Iwama E, Ijichi K, et al.. Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. Cancer Sci. 2020, 111:2482-7. 10.1111\/cas.14488","journal-title":"Cancer Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2019.100892","article-title":"Organizing pneumonia secondary to lung cancer of unknown primary site","volume":"28","author":"Mao R","year":"2019","unstructured":"Mao R, Zhang L, Hou J, Zou Y, Zhu L, Chen Z. Organizing pneumonia secondary to lung cancer of unknown primary site. Respir Med Case Rep. 2019, 28:100892. 10.1016\/j.rmcr.2019.100892","journal-title":"Respir Med Case Rep"},{"key":"ref17","article-title":"Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease","volume":"30","author":"Shukuya T","year":"2010","unstructured":"Shukuya T, Ishiwata T, Hara M, et al.. Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res. 2010, 30:4357-62.","journal-title":"Anticancer Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2590-x","article-title":"The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease","volume":"74","author":"Shimizu R","year":"2014","unstructured":"Shimizu R, Fujimoto D, Kato R, et al.. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease. Cancer Chemother Pharmacol. 2014, 74:1159-66. 10.1007\/s00280-014-2590-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2010.04.014","article-title":"The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias","volume":"71","author":"Minegishi Y","year":"2011","unstructured":"Minegishi Y, Sudoh J, Kuribayasi H, et al.. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2011, 71:70-4. 10.1016\/j.lungcan.2010.04.014","journal-title":"Lung Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi L","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al.. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014, 370:2071-82. 10.1056\/NEJMoa1402584","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS\u00ae trials","volume":"113","author":"Richeldi L","year":"2016","unstructured":"Richeldi L, Cottin V, du Bois RM, et al.. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS\u00ae trials. Respir Med. 2016, 113:74-9. 10.1016\/j.rmed.2016.02.001","journal-title":"Respir Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck M","year":"2014","unstructured":"Reck M, Kaiser R, Mellemgaard A, et al.. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014, 15:143-55. 10.1016\/S1470-2045(13)70586-2","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.06.003","article-title":"Treatment rationale and design for J-SONIC: a\u00a0randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis","volume":"19","author":"Otsubo K","year":"2018","unstructured":"Otsubo K, Kishimoto J, Kenmotsu H, et al.. Treatment rationale and design for J-SONIC: a\u00a0randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis. Clin Lung Cancer. 2018, 19:e5-9. 10.1016\/j.cllc.2017.06.003","journal-title":"Clin Lung Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyx010","article-title":"Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma\/non-small cell lung cancer)","volume":"47","author":"Tomii K","year":"2017","unstructured":"Tomii K, Kato T, Takahashi M, et al.. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma\/non-small cell lung cancer). Jpn J Clin Oncol. 2017, 47:350-6. 10.1093\/jjco\/hyx010","journal-title":"Jpn J Clin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo K","year":"2013","unstructured":"Kubo K, Azuma A, Kanazawa M, et al.. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013, 51:260-77. 10.1016\/j.resinv.2013.09.001","journal-title":"Respir Investig"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/81178-idiopathic-pulmonary-fibrosis-complicated-by-adenocarcinoma-and-organizing-pneumonia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:38Z","timestamp":1707507278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/81178-idiopathic-pulmonary-fibrosis-complicated-by-adenocarcinoma-and-organizing-pneumonia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.20916","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,4]]}}}